nodes	percent_of_prediction	percent_of_DWPC	metapath
Gliclazide—VEGFA—sarcoma	0.738	1	CbGaD
Gliclazide—KCNJ11—mammary gland—sarcoma	0.0015	0.0774	CbGeAlD
Gliclazide—VEGFA—myometrium—sarcoma	0.00148	0.0768	CbGeAlD
Gliclazide—ABCC8—mammary gland—sarcoma	0.00138	0.0713	CbGeAlD
Gliclazide—VEGFA—S1P1 pathway—PDGFRB—sarcoma	0.00131	0.0124	CbGpPWpGaD
Gliclazide—VEGFA—Heart Development—VEGFC—sarcoma	0.0012	0.0114	CbGpPWpGaD
Gliclazide—VEGFA—HIF-2-alpha transcription factor network—FLT1—sarcoma	0.00118	0.0112	CbGpPWpGaD
Gliclazide—VEGFA—VEGFR2 mediated cell proliferation—PLCG1—sarcoma	0.00116	0.011	CbGpPWpGaD
Gliclazide—VEGFA—Beta1 integrin cell surface interactions—COL18A1—sarcoma	0.00115	0.0108	CbGpPWpGaD
Gliclazide—VEGFA—smooth muscle tissue—sarcoma	0.00112	0.0581	CbGeAlD
Gliclazide—VEGFA—S1P1 pathway—KDR—sarcoma	0.00108	0.0103	CbGpPWpGaD
Gliclazide—VEGFA—Angiogenesis—PDGFRA—sarcoma	0.00107	0.0101	CbGpPWpGaD
Gliclazide—VEGFA—S1P3 pathway—PDGFRB—sarcoma	0.00105	0.00994	CbGpPWpGaD
Gliclazide—ALB—Scavenging of heme from plasma—HBA1—sarcoma	0.00103	0.00979	CbGpPWpGaD
Gliclazide—ALB—mammary gland—sarcoma	0.000987	0.0511	CbGeAlD
Gliclazide—VEGFA—cardiac atrium—sarcoma	0.000968	0.0501	CbGeAlD
Gliclazide—VEGFA—uterus—sarcoma	0.000963	0.0498	CbGeAlD
Gliclazide—VEGFA—HIF-1-alpha transcription factor network—NPM1—sarcoma	0.000928	0.00878	CbGpPWpGaD
Gliclazide—KCNJ11—hematopoietic system—sarcoma	0.000912	0.0472	CbGeAlD
Gliclazide—VEGFA—Angiogenesis—KDR—sarcoma	0.000899	0.00851	CbGpPWpGaD
Gliclazide—ABCC8—seminal vesicle—sarcoma	0.000884	0.0457	CbGeAlD
Gliclazide—VEGFA—tendon—sarcoma	0.000843	0.0436	CbGeAlD
Gliclazide—VEGFA—bone marrow—sarcoma	0.000817	0.0423	CbGeAlD
Gliclazide—VEGFA—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—JUN—sarcoma	0.000784	0.00742	CbGpPWpGaD
Gliclazide—VEGFA—Platelet degranulation—VEGFC—sarcoma	0.000744	0.00704	CbGpPWpGaD
Gliclazide—ABCC8—smooth muscle tissue—sarcoma	0.00074	0.0383	CbGeAlD
Gliclazide—VEGFA—Signaling events mediated by TCPTP—PDGFRB—sarcoma	0.000721	0.00683	CbGpPWpGaD
Gliclazide—VEGFA—Response to elevated platelet cytosolic Ca2+—VEGFC—sarcoma	0.000709	0.00671	CbGpPWpGaD
Gliclazide—VEGFA—testis—sarcoma	0.000698	0.0361	CbGeAlD
Gliclazide—VEGFA—Beta3 integrin cell surface interactions—PDGFRB—sarcoma	0.000681	0.00644	CbGpPWpGaD
Gliclazide—VEGFA—HIF-2-alpha transcription factor network—KDR—sarcoma	0.000681	0.00644	CbGpPWpGaD
Gliclazide—VEGFA—EPHA-mediated growth cone collapse—KDR—sarcoma	0.000681	0.00644	CbGpPWpGaD
Gliclazide—VEGFA—VEGFR2 mediated cell proliferation—KDR—sarcoma	0.000681	0.00644	CbGpPWpGaD
Gliclazide—VEGFA—Signaling events mediated by VEGFR1 and VEGFR2—FLT1—sarcoma	0.000678	0.00641	CbGpPWpGaD
Gliclazide—VEGFA—Signaling events mediated by VEGFR1 and VEGFR2—PLCG1—sarcoma	0.000666	0.0063	CbGpPWpGaD
Gliclazide—VEGFA—liver—sarcoma	0.00066	0.0342	CbGeAlD
Gliclazide—VEGFA—HIF-1-alpha transcription factor network—CXCR4—sarcoma	0.000655	0.0062	CbGpPWpGaD
Gliclazide—KCNJ11—lymphoid tissue—sarcoma	0.000642	0.0332	CbGeAlD
Gliclazide—CYP2C9—mammary gland—sarcoma	0.000616	0.0319	CbGeAlD
Gliclazide—KCNJ11—tendon—sarcoma	0.000603	0.0312	CbGeAlD
Gliclazide—VEGFA—Signaling events mediated by TCPTP—KDR—sarcoma	0.000598	0.00566	CbGpPWpGaD
Gliclazide—VEGFA—Beta3 integrin cell surface interactions—KDR—sarcoma	0.000564	0.00534	CbGpPWpGaD
Gliclazide—VEGFA—SHP2 signaling—IGF1R—sarcoma	0.000564	0.00534	CbGpPWpGaD
Gliclazide—VEGFA—Signaling by VEGF—VEGFC—sarcoma	0.000557	0.00527	CbGpPWpGaD
Gliclazide—VEGFA—SHP2 signaling—PDGFRB—sarcoma	0.000536	0.00507	CbGpPWpGaD
Gliclazide—VEGFA—Bladder Cancer—MDM2—sarcoma	0.000532	0.00503	CbGpPWpGaD
Gliclazide—ABCC8—FOXA2 and FOXA3 transcription factor networks—CREB1—sarcoma	0.000532	0.00503	CbGpPWpGaD
Gliclazide—VEGFA—Integrins in angiogenesis—IGF1R—sarcoma	0.000528	0.00499	CbGpPWpGaD
Gliclazide—VEGFA—Endochondral Ossification—IGF1R—sarcoma	0.000521	0.00493	CbGpPWpGaD
Gliclazide—KCNJ11—FOXA2 and FOXA3 transcription factor networks—CREB1—sarcoma	0.000515	0.00488	CbGpPWpGaD
Gliclazide—VEGFA—Angiogenesis—SRC—sarcoma	0.000509	0.00481	CbGpPWpGaD
Gliclazide—VEGFA—lymph node—sarcoma	0.000506	0.0262	CbGeAlD
Gliclazide—VEGFA—S1P3 pathway—SRC—sarcoma	0.000492	0.00466	CbGpPWpGaD
Gliclazide—VEGFA—Alpha9 beta1 integrin signaling events—SRC—sarcoma	0.000492	0.00466	CbGpPWpGaD
Gliclazide—CYP2C19—hematopoietic system—sarcoma	0.000484	0.0251	CbGeAlD
Gliclazide—VEGFA—Glypican 1 network—SRC—sarcoma	0.000477	0.00452	CbGpPWpGaD
Gliclazide—VEGFA—Differentiation Pathway—KIT—sarcoma	0.000476	0.0045	CbGpPWpGaD
Gliclazide—VEGFA—VEGFA-VEGFR2 Pathway—PLCG1—sarcoma	0.000463	0.00439	CbGpPWpGaD
Gliclazide—VEGFA—Bladder Cancer—CCND1—sarcoma	0.000463	0.00438	CbGpPWpGaD
Gliclazide—ABCC8—testis—sarcoma	0.00046	0.0238	CbGeAlD
Gliclazide—VEGFA—Signaling by VEGF—FLT1—sarcoma	0.000445	0.00421	CbGpPWpGaD
Gliclazide—VEGFA—SHP2 signaling—KDR—sarcoma	0.000444	0.0042	CbGpPWpGaD
Gliclazide—VEGFA—Signaling by VEGF—PLCG1—sarcoma	0.000438	0.00414	CbGpPWpGaD
Gliclazide—VEGFA—Integrins in angiogenesis—KDR—sarcoma	0.000416	0.00393	CbGpPWpGaD
Gliclazide—ALB—Binding and Uptake of Ligands by Scavenger Receptors—HBA1—sarcoma	0.000413	0.0039	CbGpPWpGaD
Gliclazide—VEGFA—Allograft Rejection—PDGFRA—sarcoma	0.000412	0.0039	CbGpPWpGaD
Gliclazide—VEGFA—Signaling events mediated by VEGFR1 and VEGFR2—KDR—sarcoma	0.000391	0.0037	CbGpPWpGaD
Gliclazide—VEGFA—EPHA-mediated growth cone collapse—SRC—sarcoma	0.000385	0.00364	CbGpPWpGaD
Gliclazide—VEGFA—VEGFR2 mediated cell proliferation—SRC—sarcoma	0.000385	0.00364	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—WT1—sarcoma	0.000383	0.00362	CbGpPWpGaD
Gliclazide—CYP2C9—hematopoietic system—sarcoma	0.000375	0.0194	CbGeAlD
Gliclazide—VEGFA—Focal Adhesion—VEGFC—sarcoma	0.000373	0.00353	CbGpPWpGaD
Gliclazide—VEGFA—Bladder Cancer—MYC—sarcoma	0.000371	0.00352	CbGpPWpGaD
Gliclazide—VEGFA—VEGFR2 mediated cell proliferation—NRAS—sarcoma	0.00037	0.0035	CbGpPWpGaD
Gliclazide—VEGFA—Bladder Cancer—EGFR—sarcoma	0.000363	0.00344	CbGpPWpGaD
Gliclazide—KCNJ11—lymph node—sarcoma	0.000362	0.0187	CbGeAlD
Gliclazide—VEGFA—Oncostatin M Signaling Pathway—CREB1—sarcoma	0.000355	0.00336	CbGpPWpGaD
Gliclazide—VEGFA—HIF-1-alpha transcription factor network—CREB1—sarcoma	0.000351	0.00332	CbGpPWpGaD
Gliclazide—VEGFA—Heart Development—CTNNB1—sarcoma	0.000347	0.00328	CbGpPWpGaD
Gliclazide—ALB—Vitamin B12 Metabolism—HBA1—sarcoma	0.000347	0.00328	CbGpPWpGaD
Gliclazide—VEGFA—Signaling events mediated by TCPTP—SRC—sarcoma	0.000338	0.0032	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Breast Cancer Pathway—ATF1—sarcoma	0.000334	0.00316	CbGpPWpGaD
Gliclazide—VEGFA—Axon guidance—EZR—sarcoma	0.000331	0.00313	CbGpPWpGaD
Gliclazide—VEGFA—Platelet activation, signaling and aggregation—VEGFC—sarcoma	0.00033	0.00312	CbGpPWpGaD
Gliclazide—ALB—testis—sarcoma	0.00033	0.0171	CbGeAlD
Gliclazide—VEGFA—VEGFR2 mediated cell proliferation—KRAS—sarcoma	0.000319	0.00302	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—MYOG—sarcoma	0.000312	0.00295	CbGpPWpGaD
Gliclazide—ALB—liver—sarcoma	0.000312	0.0161	CbGeAlD
Gliclazide—VEGFA—Bladder Cancer—TP53—sarcoma	0.000305	0.00289	CbGpPWpGaD
Gliclazide—VEGFA—Aryl Hydrocarbon Receptor—SRC—sarcoma	0.000302	0.00286	CbGpPWpGaD
Gliclazide—VEGFA—EPH-Ephrin signaling—KDR—sarcoma	0.000302	0.00286	CbGpPWpGaD
Gliclazide—VEGFA—Focal Adhesion—FLT1—sarcoma	0.000298	0.00282	CbGpPWpGaD
Gliclazide—VEGFA—Signaling events mediated by TCPTP—EGFR—sarcoma	0.000296	0.0028	CbGpPWpGaD
Gliclazide—CYP2C19—Melatonin metabolism and effects—FOXO1—sarcoma	0.000296	0.0028	CbGpPWpGaD
Gliclazide—VEGFA—Bladder Cancer—HRAS—sarcoma	0.000292	0.00276	CbGpPWpGaD
Gliclazide—VEGFA—Aryl Hydrocarbon Receptor—NRAS—sarcoma	0.000291	0.00275	CbGpPWpGaD
Gliclazide—VEGFA—SHP2 signaling—IL2—sarcoma	0.000288	0.00272	CbGpPWpGaD
Gliclazide—ALB—Folate Metabolism—HBA1—sarcoma	0.000282	0.00267	CbGpPWpGaD
Gliclazide—CYP2C19—Constitutive Androstane Receptor Pathway—FOXO1—sarcoma	0.000274	0.00259	CbGpPWpGaD
Gliclazide—VEGFA—VEGFA-VEGFR2 Pathway—KDR—sarcoma	0.000272	0.00257	CbGpPWpGaD
Gliclazide—VEGFA—VEGFR2 mediated cell proliferation—HRAS—sarcoma	0.000271	0.00256	CbGpPWpGaD
Gliclazide—VEGFA—Aryl Hydrocarbon Receptor—MYC—sarcoma	0.000271	0.00256	CbGpPWpGaD
Gliclazide—VEGFA—Aryl Hydrocarbon Receptor—EGFR—sarcoma	0.000265	0.00251	CbGpPWpGaD
Gliclazide—ALB—Platelet degranulation—VEGFC—sarcoma	0.000263	0.00249	CbGpPWpGaD
Gliclazide—VEGFA—Signaling by VEGF—KDR—sarcoma	0.000257	0.00243	CbGpPWpGaD
Gliclazide—VEGFA—HIF-1-alpha transcription factor network—JUN—sarcoma	0.000252	0.00239	CbGpPWpGaD
Gliclazide—CYP2C19—liver—sarcoma	0.000251	0.013	CbGeAlD
Gliclazide—VEGFA—Aryl Hydrocarbon Receptor—KRAS—sarcoma	0.00025	0.00237	CbGpPWpGaD
Gliclazide—ALB—Response to elevated platelet cytosolic Ca2+—VEGFC—sarcoma	0.00025	0.00237	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Breast Cancer Pathway—FOXO1—sarcoma	0.00025	0.00236	CbGpPWpGaD
Gliclazide—CYP2C9—Constitutive Androstane Receptor Pathway—FOXO1—sarcoma	0.00025	0.00236	CbGpPWpGaD
Gliclazide—VEGFA—EPH-Ephrin signaling—MMP2—sarcoma	0.000246	0.00233	CbGpPWpGaD
Gliclazide—VEGFA—Signaling events mediated by VEGFR1 and VEGFR2—CTNNB1—sarcoma	0.000245	0.00231	CbGpPWpGaD
Gliclazide—VEGFA—SHP2 signaling—NRAS—sarcoma	0.000242	0.00229	CbGpPWpGaD
Gliclazide—ALB—lymph node—sarcoma	0.000239	0.0124	CbGeAlD
Gliclazide—VEGFA—Developmental Biology—EZR—sarcoma	0.000236	0.00224	CbGpPWpGaD
Gliclazide—VEGFA—Integrins in angiogenesis—SRC—sarcoma	0.000235	0.00222	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—TEK—sarcoma	0.000232	0.00219	CbGpPWpGaD
Gliclazide—VEGFA—Oncostatin M Signaling Pathway—SRC—sarcoma	0.000229	0.00217	CbGpPWpGaD
Gliclazide—VEGFA—Allograft Rejection—IL2—sarcoma	0.000225	0.00213	CbGpPWpGaD
Gliclazide—ALB—Selenium Micronutrient Network—HBA1—sarcoma	0.000224	0.00212	CbGpPWpGaD
Gliclazide—VEGFA—Signaling events mediated by VEGFR1 and VEGFR2—SRC—sarcoma	0.000221	0.00209	CbGpPWpGaD
Gliclazide—VEGFA—SHP2 signaling—EGFR—sarcoma	0.00022	0.00208	CbGpPWpGaD
Gliclazide—VEGFA—Focal Adhesion—IGF1R—sarcoma	0.000218	0.00207	CbGpPWpGaD
Gliclazide—VEGFA—Aryl Hydrocarbon Receptor—HRAS—sarcoma	0.000213	0.00201	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—ANGPT2—sarcoma	0.000212	0.00201	CbGpPWpGaD
Gliclazide—VEGFA—SHP2 signaling—KRAS—sarcoma	0.000208	0.00197	CbGpPWpGaD
Gliclazide—VEGFA—Focal Adhesion—PDGFRB—sarcoma	0.000207	0.00196	CbGpPWpGaD
Gliclazide—VEGFA—Focal Adhesion—PDGFRA—sarcoma	0.000204	0.00193	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—PDGFRA—sarcoma	0.000203	0.00192	CbGpPWpGaD
Gliclazide—VEGFA—Axon guidance—PTPRC—sarcoma	0.000195	0.00185	CbGpPWpGaD
Gliclazide—CYP2C9—liver—sarcoma	0.000194	0.0101	CbGeAlD
Gliclazide—VEGFA—Developmental Biology—MYOD1—sarcoma	0.000193	0.00182	CbGpPWpGaD
Gliclazide—VEGFA—Axon guidance—PLCG1—sarcoma	0.000191	0.00181	CbGpPWpGaD
Gliclazide—VEGFA—Oncostatin M Signaling Pathway—KRAS—sarcoma	0.00019	0.0018	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Breast Cancer Pathway—CREB1—sarcoma	0.000181	0.00171	CbGpPWpGaD
Gliclazide—VEGFA—SHP2 signaling—HRAS—sarcoma	0.000177	0.00167	CbGpPWpGaD
Gliclazide—VEGFA—SIDS Susceptibility Pathways—CREB1—sarcoma	0.000176	0.00167	CbGpPWpGaD
Gliclazide—VEGFA—Focal Adhesion—KDR—sarcoma	0.000172	0.00163	CbGpPWpGaD
Gliclazide—ALB—FOXA2 and FOXA3 transcription factor networks—CREB1—sarcoma	0.000171	0.00162	CbGpPWpGaD
Gliclazide—VEGFA—EPH-Ephrin signaling—SRC—sarcoma	0.000171	0.00161	CbGpPWpGaD
Gliclazide—VEGFA—VEGFA-VEGFR2 Pathway—CTNNB1—sarcoma	0.00017	0.00161	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—VEGFC—sarcoma	0.00017	0.00161	CbGpPWpGaD
Gliclazide—VEGFA—Oncostatin M Signaling Pathway—TP53—sarcoma	0.000169	0.0016	CbGpPWpGaD
Gliclazide—VEGFA—Oncostatin M Signaling Pathway—HRAS—sarcoma	0.000161	0.00153	CbGpPWpGaD
Gliclazide—VEGFA—Signaling by VEGF—CTNNB1—sarcoma	0.000161	0.00152	CbGpPWpGaD
Gliclazide—VEGFA—VEGFA-VEGFR2 Pathway—SRC—sarcoma	0.000154	0.00146	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—CREB1—sarcoma	0.00015	0.00142	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Breast Cancer Pathway—MDM2—sarcoma	0.00015	0.00142	CbGpPWpGaD
Gliclazide—VEGFA—VEGFA-VEGFR2 Pathway—NRAS—sarcoma	0.000148	0.0014	CbGpPWpGaD
Gliclazide—Asthenia—Dactinomycin—sarcoma	0.000146	0.00106	CcSEcCtD
Gliclazide—Feeling abnormal—Mitoxantrone—sarcoma	0.000146	0.00106	CcSEcCtD
Gliclazide—VEGFA—Signaling by VEGF—SRC—sarcoma	0.000145	0.00137	CbGpPWpGaD
Gliclazide—Asthma—Epirubicin—sarcoma	0.000145	0.00105	CcSEcCtD
Gliclazide—Pruritus—Thiotepa—sarcoma	0.000145	0.00105	CcSEcCtD
Gliclazide—Gastrointestinal pain—Mitoxantrone—sarcoma	0.000145	0.00105	CcSEcCtD
Gliclazide—Thrombocytopenia—Etoposide—sarcoma	0.000144	0.00105	CcSEcCtD
Gliclazide—Tachycardia—Etoposide—sarcoma	0.000143	0.00104	CcSEcCtD
Gliclazide—Abdominal pain—Vincristine—sarcoma	0.000143	0.00104	CcSEcCtD
Gliclazide—Body temperature increased—Vincristine—sarcoma	0.000143	0.00104	CcSEcCtD
Gliclazide—Skin disorder—Etoposide—sarcoma	0.000143	0.00104	CcSEcCtD
Gliclazide—Dry skin—Doxorubicin—sarcoma	0.000142	0.00103	CcSEcCtD
Gliclazide—Hyperhidrosis—Etoposide—sarcoma	0.000142	0.00103	CcSEcCtD
Gliclazide—Angina pectoris—Epirubicin—sarcoma	0.000141	0.00103	CcSEcCtD
Gliclazide—Urticaria—Mitoxantrone—sarcoma	0.00014	0.00102	CcSEcCtD
Gliclazide—Diarrhoea—Thiotepa—sarcoma	0.00014	0.00102	CcSEcCtD
Gliclazide—VEGFA—Signaling by VEGF—NRAS—sarcoma	0.00014	0.00132	CbGpPWpGaD
Gliclazide—Abdominal pain—Mitoxantrone—sarcoma	0.00014	0.00102	CcSEcCtD
Gliclazide—Body temperature increased—Mitoxantrone—sarcoma	0.00014	0.00102	CcSEcCtD
Gliclazide—Toxic epidermal necrolysis—Doxorubicin—sarcoma	0.00014	0.00102	CcSEcCtD
Gliclazide—Bronchitis—Epirubicin—sarcoma	0.000139	0.00101	CcSEcCtD
Gliclazide—VEGFA—Developmental Biology—PTPRC—sarcoma	0.000139	0.00132	CbGpPWpGaD
Gliclazide—Diarrhoea—Dactinomycin—sarcoma	0.000139	0.00101	CcSEcCtD
Gliclazide—Pancytopenia—Epirubicin—sarcoma	0.000138	0.001	CcSEcCtD
Gliclazide—Hypotension—Etoposide—sarcoma	0.000137	0.000999	CcSEcCtD
Gliclazide—Gastritis—Doxorubicin—sarcoma	0.000137	0.000998	CcSEcCtD
Gliclazide—VEGFA—Developmental Biology—PLCG1—sarcoma	0.000136	0.00129	CbGpPWpGaD
Gliclazide—Dizziness—Thiotepa—sarcoma	0.000135	0.000984	CcSEcCtD
Gliclazide—Abdominal distension—Doxorubicin—sarcoma	0.000135	0.000981	CcSEcCtD
Gliclazide—Upper respiratory tract infection—Epirubicin—sarcoma	0.000135	0.000979	CcSEcCtD
Gliclazide—Asthma—Doxorubicin—sarcoma	0.000134	0.000975	CcSEcCtD
Gliclazide—VEGFA—Hemostasis—PLCG1—sarcoma	0.000134	0.00127	CbGpPWpGaD
Gliclazide—Hypersensitivity—Vincristine—sarcoma	0.000134	0.000972	CcSEcCtD
Gliclazide—Photosensitivity reaction—Epirubicin—sarcoma	0.000132	0.000962	CcSEcCtD
Gliclazide—Paraesthesia—Etoposide—sarcoma	0.000132	0.00096	CcSEcCtD
Gliclazide—Weight increased—Epirubicin—sarcoma	0.000132	0.000959	CcSEcCtD
Gliclazide—Dyspnoea—Etoposide—sarcoma	0.000131	0.000953	CcSEcCtD
Gliclazide—Hyperglycaemia—Epirubicin—sarcoma	0.000131	0.00095	CcSEcCtD
Gliclazide—Somnolence—Etoposide—sarcoma	0.000131	0.00095	CcSEcCtD
Gliclazide—Angina pectoris—Doxorubicin—sarcoma	0.000131	0.00095	CcSEcCtD
Gliclazide—VEGFA—Integrated Breast Cancer Pathway—CCND1—sarcoma	0.00013	0.00123	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Breast Cancer Pathway—JUN—sarcoma	0.00013	0.00123	CbGpPWpGaD
Gliclazide—Hypersensitivity—Mitoxantrone—sarcoma	0.00013	0.000947	CcSEcCtD
Gliclazide—Asthenia—Vincristine—sarcoma	0.00013	0.000947	CcSEcCtD
Gliclazide—Vomiting—Thiotepa—sarcoma	0.00013	0.000946	CcSEcCtD
Gliclazide—Pneumonia—Epirubicin—sarcoma	0.00013	0.000945	CcSEcCtD
Gliclazide—VEGFA—Integrated Breast Cancer Pathway—CTNNB1—sarcoma	0.000129	0.00122	CbGpPWpGaD
Gliclazide—Drowsiness—Epirubicin—sarcoma	0.000129	0.000939	CcSEcCtD
Gliclazide—Vomiting—Dactinomycin—sarcoma	0.000129	0.000939	CcSEcCtD
Gliclazide—Rash—Thiotepa—sarcoma	0.000129	0.000938	CcSEcCtD
Gliclazide—Bronchitis—Doxorubicin—sarcoma	0.000129	0.000938	CcSEcCtD
Gliclazide—Dermatitis—Thiotepa—sarcoma	0.000129	0.000937	CcSEcCtD
Gliclazide—Headache—Thiotepa—sarcoma	0.000128	0.000932	CcSEcCtD
Gliclazide—Stevens-Johnson syndrome—Epirubicin—sarcoma	0.000128	0.000931	CcSEcCtD
Gliclazide—Rash—Dactinomycin—sarcoma	0.000128	0.000931	CcSEcCtD
Gliclazide—VEGFA—VEGFA-VEGFR2 Pathway—KRAS—sarcoma	0.000127	0.00121	CbGpPWpGaD
Gliclazide—Pancytopenia—Doxorubicin—sarcoma	0.000127	0.000926	CcSEcCtD
Gliclazide—Renal failure—Epirubicin—sarcoma	0.000127	0.000923	CcSEcCtD
Gliclazide—Gastrointestinal disorder—Etoposide—sarcoma	0.000127	0.000923	CcSEcCtD
Gliclazide—VEGFA—SIDS Susceptibility Pathways—JUN—sarcoma	0.000127	0.0012	CbGpPWpGaD
Gliclazide—Asthenia—Mitoxantrone—sarcoma	0.000127	0.000922	CcSEcCtD
Gliclazide—Fatigue—Etoposide—sarcoma	0.000127	0.000922	CcSEcCtD
Gliclazide—Neuropathy peripheral—Epirubicin—sarcoma	0.000127	0.000921	CcSEcCtD
Gliclazide—Jaundice—Epirubicin—sarcoma	0.000126	0.000916	CcSEcCtD
Gliclazide—VEGFA—SIDS Susceptibility Pathways—CTNNB1—sarcoma	0.000126	0.00119	CbGpPWpGaD
Gliclazide—Pain—Etoposide—sarcoma	0.000126	0.000914	CcSEcCtD
Gliclazide—Constipation—Etoposide—sarcoma	0.000126	0.000914	CcSEcCtD
Gliclazide—Urinary tract infection—Epirubicin—sarcoma	0.000126	0.000913	CcSEcCtD
Gliclazide—Conjunctivitis—Epirubicin—sarcoma	0.000126	0.000913	CcSEcCtD
Gliclazide—Upper respiratory tract infection—Doxorubicin—sarcoma	0.000125	0.000906	CcSEcCtD
Gliclazide—Diarrhoea—Vincristine—sarcoma	0.000124	0.000903	CcSEcCtD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—MDM2—sarcoma	0.000124	0.00117	CbGpPWpGaD
Gliclazide—Sweating—Epirubicin—sarcoma	0.000124	0.000901	CcSEcCtD
Gliclazide—Photosensitivity reaction—Doxorubicin—sarcoma	0.000122	0.00089	CcSEcCtD
Gliclazide—Hepatobiliary disease—Epirubicin—sarcoma	0.000122	0.000888	CcSEcCtD
Gliclazide—Weight increased—Doxorubicin—sarcoma	0.000122	0.000887	CcSEcCtD
Gliclazide—Epistaxis—Epirubicin—sarcoma	0.000122	0.000886	CcSEcCtD
Gliclazide—Nausea—Thiotepa—sarcoma	0.000122	0.000884	CcSEcCtD
Gliclazide—ABCC8—Neuronal System—CREB1—sarcoma	0.000121	0.00115	CbGpPWpGaD
Gliclazide—Sinusitis—Epirubicin—sarcoma	0.000121	0.000881	CcSEcCtD
Gliclazide—Feeling abnormal—Etoposide—sarcoma	0.000121	0.000881	CcSEcCtD
Gliclazide—Hyperglycaemia—Doxorubicin—sarcoma	0.000121	0.000879	CcSEcCtD
Gliclazide—Diarrhoea—Mitoxantrone—sarcoma	0.000121	0.000879	CcSEcCtD
Gliclazide—Nausea—Dactinomycin—sarcoma	0.000121	0.000877	CcSEcCtD
Gliclazide—Agranulocytosis—Epirubicin—sarcoma	0.000121	0.000877	CcSEcCtD
Gliclazide—VEGFA—Signaling by VEGF—KRAS—sarcoma	0.00012	0.00114	CbGpPWpGaD
Gliclazide—Pneumonia—Doxorubicin—sarcoma	0.00012	0.000874	CcSEcCtD
Gliclazide—Gastrointestinal pain—Etoposide—sarcoma	0.00012	0.000874	CcSEcCtD
Gliclazide—VEGFA—EPH-Ephrin signaling—HRAS—sarcoma	0.00012	0.00114	CbGpPWpGaD
Gliclazide—Dizziness—Vincristine—sarcoma	0.00012	0.000873	CcSEcCtD
Gliclazide—Drowsiness—Doxorubicin—sarcoma	0.00012	0.000869	CcSEcCtD
Gliclazide—Stevens-Johnson syndrome—Doxorubicin—sarcoma	0.000119	0.000862	CcSEcCtD
Gliclazide—Bradycardia—Epirubicin—sarcoma	0.000118	0.000859	CcSEcCtD
Gliclazide—KCNJ11—Neuronal System—CREB1—sarcoma	0.000118	0.00111	CbGpPWpGaD
Gliclazide—Renal failure—Doxorubicin—sarcoma	0.000118	0.000854	CcSEcCtD
Gliclazide—Neuropathy peripheral—Doxorubicin—sarcoma	0.000117	0.000852	CcSEcCtD
Gliclazide—Urticaria—Etoposide—sarcoma	0.000117	0.000849	CcSEcCtD
Gliclazide—Jaundice—Doxorubicin—sarcoma	0.000117	0.000847	CcSEcCtD
Gliclazide—ALB—Platelet activation, signaling and aggregation—VEGFC—sarcoma	0.000117	0.0011	CbGpPWpGaD
Gliclazide—Rhinitis—Epirubicin—sarcoma	0.000116	0.000845	CcSEcCtD
Gliclazide—Abdominal pain—Etoposide—sarcoma	0.000116	0.000845	CcSEcCtD
Gliclazide—Body temperature increased—Etoposide—sarcoma	0.000116	0.000845	CcSEcCtD
Gliclazide—Urinary tract infection—Doxorubicin—sarcoma	0.000116	0.000845	CcSEcCtD
Gliclazide—Conjunctivitis—Doxorubicin—sarcoma	0.000116	0.000845	CcSEcCtD
Gliclazide—Hepatitis—Epirubicin—sarcoma	0.000116	0.000843	CcSEcCtD
Gliclazide—Hypoaesthesia—Epirubicin—sarcoma	0.000115	0.000839	CcSEcCtD
Gliclazide—Vomiting—Vincristine—sarcoma	0.000115	0.000839	CcSEcCtD
Gliclazide—Pharyngitis—Epirubicin—sarcoma	0.000115	0.000837	CcSEcCtD
Gliclazide—Sweating—Doxorubicin—sarcoma	0.000115	0.000833	CcSEcCtD
Gliclazide—Rash—Vincristine—sarcoma	0.000114	0.000832	CcSEcCtD
Gliclazide—Dermatitis—Vincristine—sarcoma	0.000114	0.000831	CcSEcCtD
Gliclazide—Oedema peripheral—Epirubicin—sarcoma	0.000114	0.000831	CcSEcCtD
Gliclazide—Headache—Vincristine—sarcoma	0.000114	0.000827	CcSEcCtD
Gliclazide—Hepatobiliary disease—Doxorubicin—sarcoma	0.000113	0.000822	CcSEcCtD
Gliclazide—Epistaxis—Doxorubicin—sarcoma	0.000113	0.00082	CcSEcCtD
Gliclazide—Vomiting—Mitoxantrone—sarcoma	0.000112	0.000817	CcSEcCtD
Gliclazide—Sinusitis—Doxorubicin—sarcoma	0.000112	0.000816	CcSEcCtD
Gliclazide—VEGFA—Axon guidance—KDR—sarcoma	0.000112	0.00106	CbGpPWpGaD
Gliclazide—Visual impairment—Epirubicin—sarcoma	0.000112	0.000813	CcSEcCtD
Gliclazide—Agranulocytosis—Doxorubicin—sarcoma	0.000112	0.000811	CcSEcCtD
Gliclazide—Rash—Mitoxantrone—sarcoma	0.000111	0.00081	CcSEcCtD
Gliclazide—Dermatitis—Mitoxantrone—sarcoma	0.000111	0.000809	CcSEcCtD
Gliclazide—Headache—Mitoxantrone—sarcoma	0.000111	0.000805	CcSEcCtD
Gliclazide—Erythema multiforme—Epirubicin—sarcoma	0.00011	0.000797	CcSEcCtD
Gliclazide—Bradycardia—Doxorubicin—sarcoma	0.000109	0.000794	CcSEcCtD
Gliclazide—VEGFA—Focal Adhesion—CCND1—sarcoma	0.000109	0.00103	CbGpPWpGaD
Gliclazide—Eye disorder—Epirubicin—sarcoma	0.000108	0.000788	CcSEcCtD
Gliclazide—VEGFA—Focal Adhesion—JUN—sarcoma	0.000108	0.00103	CbGpPWpGaD
Gliclazide—Hypersensitivity—Etoposide—sarcoma	0.000108	0.000788	CcSEcCtD
Gliclazide—VEGFA—VEGFA-VEGFR2 Pathway—HRAS—sarcoma	0.000108	0.00102	CbGpPWpGaD
Gliclazide—Tinnitus—Epirubicin—sarcoma	0.000108	0.000786	CcSEcCtD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—CCND1—sarcoma	0.000108	0.00102	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—JUN—sarcoma	0.000108	0.00102	CbGpPWpGaD
Gliclazide—Nausea—Vincristine—sarcoma	0.000108	0.000784	CcSEcCtD
Gliclazide—Flushing—Epirubicin—sarcoma	0.000108	0.000783	CcSEcCtD
Gliclazide—Rhinitis—Doxorubicin—sarcoma	0.000108	0.000782	CcSEcCtD
Gliclazide—VEGFA—Focal Adhesion—CTNNB1—sarcoma	0.000108	0.00102	CbGpPWpGaD
Gliclazide—Hepatitis—Doxorubicin—sarcoma	0.000107	0.00078	CcSEcCtD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—CTNNB1—sarcoma	0.000107	0.00101	CbGpPWpGaD
Gliclazide—Hypoaesthesia—Doxorubicin—sarcoma	0.000107	0.000776	CcSEcCtD
Gliclazide—Pharyngitis—Doxorubicin—sarcoma	0.000107	0.000774	CcSEcCtD
Gliclazide—Oedema peripheral—Doxorubicin—sarcoma	0.000106	0.000769	CcSEcCtD
Gliclazide—Asthenia—Etoposide—sarcoma	0.000105	0.000767	CcSEcCtD
Gliclazide—Nausea—Mitoxantrone—sarcoma	0.000105	0.000763	CcSEcCtD
Gliclazide—VEGFA—Integrated Breast Cancer Pathway—MYC—sarcoma	0.000105	0.00099	CbGpPWpGaD
Gliclazide—Chills—Epirubicin—sarcoma	0.000104	0.000757	CcSEcCtD
Gliclazide—Pruritus—Etoposide—sarcoma	0.000104	0.000756	CcSEcCtD
Gliclazide—Arrhythmia—Epirubicin—sarcoma	0.000104	0.000753	CcSEcCtD
Gliclazide—Visual impairment—Doxorubicin—sarcoma	0.000103	0.000752	CcSEcCtD
Gliclazide—VEGFA—Integrated Breast Cancer Pathway—EGFR—sarcoma	0.000102	0.000969	CbGpPWpGaD
Gliclazide—VEGFA—Signaling by VEGF—HRAS—sarcoma	0.000102	0.000967	CbGpPWpGaD
Gliclazide—Mental disorder—Epirubicin—sarcoma	0.000102	0.000739	CcSEcCtD
Gliclazide—Erythema multiforme—Doxorubicin—sarcoma	0.000101	0.000738	CcSEcCtD
Gliclazide—Malnutrition—Epirubicin—sarcoma	0.000101	0.000734	CcSEcCtD
Gliclazide—Erythema—Epirubicin—sarcoma	0.000101	0.000734	CcSEcCtD
Gliclazide—Diarrhoea—Etoposide—sarcoma	0.000101	0.000731	CcSEcCtD
Gliclazide—ABCC8—Neuronal System—MDM2—sarcoma	0.0001	0.000949	CbGpPWpGaD
Gliclazide—Eye disorder—Doxorubicin—sarcoma	0.0001	0.000729	CcSEcCtD
Gliclazide—Tinnitus—Doxorubicin—sarcoma	0.0001	0.000728	CcSEcCtD
Gliclazide—Flushing—Doxorubicin—sarcoma	9.96e-05	0.000724	CcSEcCtD
Gliclazide—Flatulence—Epirubicin—sarcoma	9.95e-05	0.000723	CcSEcCtD
Gliclazide—Tension—Epirubicin—sarcoma	9.91e-05	0.00072	CcSEcCtD
Gliclazide—VEGFA—Platelet activation, signaling and aggregation—IL2—sarcoma	9.87e-05	0.000934	CbGpPWpGaD
Gliclazide—VEGFA—Axon guidance—CREB1—sarcoma	9.83e-05	0.00093	CbGpPWpGaD
Gliclazide—Nervousness—Epirubicin—sarcoma	9.81e-05	0.000713	CcSEcCtD
Gliclazide—Back pain—Epirubicin—sarcoma	9.77e-05	0.00071	CcSEcCtD
Gliclazide—KCNJ11—Neuronal System—MDM2—sarcoma	9.73e-05	0.000921	CbGpPWpGaD
Gliclazide—Dizziness—Etoposide—sarcoma	9.72e-05	0.000707	CcSEcCtD
Gliclazide—VEGFA—Focal Adhesion—SRC—sarcoma	9.72e-05	0.00092	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—SRC—sarcoma	9.68e-05	0.000916	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—FOXO1—sarcoma	9.67e-05	0.000915	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Breast Cancer Pathway—KRAS—sarcoma	9.67e-05	0.000915	CbGpPWpGaD
Gliclazide—Chills—Doxorubicin—sarcoma	9.63e-05	0.0007	CcSEcCtD
Gliclazide—Arrhythmia—Doxorubicin—sarcoma	9.59e-05	0.000697	CcSEcCtD
Gliclazide—VEGFA—Cellular responses to stress—MDM2—sarcoma	9.58e-05	0.000907	CbGpPWpGaD
Gliclazide—Mental disorder—Doxorubicin—sarcoma	9.4e-05	0.000684	CcSEcCtD
Gliclazide—Ill-defined disorder—Epirubicin—sarcoma	9.37e-05	0.000681	CcSEcCtD
Gliclazide—Vomiting—Etoposide—sarcoma	9.35e-05	0.00068	CcSEcCtD
Gliclazide—Erythema—Doxorubicin—sarcoma	9.34e-05	0.000679	CcSEcCtD
Gliclazide—Malnutrition—Doxorubicin—sarcoma	9.34e-05	0.000679	CcSEcCtD
Gliclazide—Anaemia—Epirubicin—sarcoma	9.33e-05	0.000679	CcSEcCtD
Gliclazide—Agitation—Epirubicin—sarcoma	9.28e-05	0.000675	CcSEcCtD
Gliclazide—Rash—Etoposide—sarcoma	9.27e-05	0.000674	CcSEcCtD
Gliclazide—Dermatitis—Etoposide—sarcoma	9.26e-05	0.000673	CcSEcCtD
Gliclazide—Headache—Etoposide—sarcoma	9.21e-05	0.00067	CcSEcCtD
Gliclazide—Flatulence—Doxorubicin—sarcoma	9.21e-05	0.000669	CcSEcCtD
Gliclazide—Tension—Doxorubicin—sarcoma	9.17e-05	0.000667	CcSEcCtD
Gliclazide—ALB—Folate Metabolism—IL2—sarcoma	9.16e-05	0.000867	CbGpPWpGaD
Gliclazide—VEGFA—Axon guidance—MMP2—sarcoma	9.15e-05	0.000866	CbGpPWpGaD
Gliclazide—Malaise—Epirubicin—sarcoma	9.11e-05	0.000662	CcSEcCtD
Gliclazide—Nervousness—Doxorubicin—sarcoma	9.07e-05	0.00066	CcSEcCtD
Gliclazide—Leukopenia—Epirubicin—sarcoma	9.04e-05	0.000657	CcSEcCtD
Gliclazide—Back pain—Doxorubicin—sarcoma	9.04e-05	0.000657	CcSEcCtD
Gliclazide—Palpitations—Epirubicin—sarcoma	8.92e-05	0.000649	CcSEcCtD
Gliclazide—Loss of consciousness—Epirubicin—sarcoma	8.87e-05	0.000645	CcSEcCtD
Gliclazide—Cough—Epirubicin—sarcoma	8.81e-05	0.000641	CcSEcCtD
Gliclazide—Convulsion—Epirubicin—sarcoma	8.75e-05	0.000636	CcSEcCtD
Gliclazide—Nausea—Etoposide—sarcoma	8.73e-05	0.000635	CcSEcCtD
Gliclazide—Hypertension—Epirubicin—sarcoma	8.72e-05	0.000634	CcSEcCtD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—MYC—sarcoma	8.67e-05	0.000821	CbGpPWpGaD
Gliclazide—Ill-defined disorder—Doxorubicin—sarcoma	8.67e-05	0.00063	CcSEcCtD
Gliclazide—Anaemia—Doxorubicin—sarcoma	8.63e-05	0.000628	CcSEcCtD
Gliclazide—VEGFA—Platelet activation, signaling and aggregation—SRC—sarcoma	8.61e-05	0.000815	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Breast Cancer Pathway—TP53—sarcoma	8.6e-05	0.000813	CbGpPWpGaD
Gliclazide—Chest pain—Epirubicin—sarcoma	8.6e-05	0.000625	CcSEcCtD
Gliclazide—Myalgia—Epirubicin—sarcoma	8.6e-05	0.000625	CcSEcCtD
Gliclazide—Arthralgia—Epirubicin—sarcoma	8.6e-05	0.000625	CcSEcCtD
Gliclazide—Agitation—Doxorubicin—sarcoma	8.59e-05	0.000624	CcSEcCtD
Gliclazide—Anxiety—Epirubicin—sarcoma	8.57e-05	0.000623	CcSEcCtD
Gliclazide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—sarcoma	8.54e-05	0.000621	CcSEcCtD
Gliclazide—VEGFA—Focal Adhesion—EGFR—sarcoma	8.52e-05	0.000806	CbGpPWpGaD
Gliclazide—Discomfort—Epirubicin—sarcoma	8.49e-05	0.000618	CcSEcCtD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—EGFR—sarcoma	8.48e-05	0.000803	CbGpPWpGaD
Gliclazide—Malaise—Doxorubicin—sarcoma	8.42e-05	0.000613	CcSEcCtD
Gliclazide—Dry mouth—Epirubicin—sarcoma	8.41e-05	0.000611	CcSEcCtD
Gliclazide—Leukopenia—Doxorubicin—sarcoma	8.36e-05	0.000608	CcSEcCtD
Gliclazide—VEGFA—Cellular responses to stress—JUN—sarcoma	8.33e-05	0.000788	CbGpPWpGaD
Gliclazide—Confusional state—Epirubicin—sarcoma	8.31e-05	0.000604	CcSEcCtD
Gliclazide—Palpitations—Doxorubicin—sarcoma	8.26e-05	0.0006	CcSEcCtD
Gliclazide—Loss of consciousness—Doxorubicin—sarcoma	8.21e-05	0.000597	CcSEcCtD
Gliclazide—Infection—Epirubicin—sarcoma	8.19e-05	0.000595	CcSEcCtD
Gliclazide—ALB—Hemostasis—TEK—sarcoma	8.18e-05	0.000774	CbGpPWpGaD
Gliclazide—Cough—Doxorubicin—sarcoma	8.15e-05	0.000593	CcSEcCtD
Gliclazide—Convulsion—Doxorubicin—sarcoma	8.09e-05	0.000589	CcSEcCtD
Gliclazide—Nervous system disorder—Epirubicin—sarcoma	8.08e-05	0.000588	CcSEcCtD
Gliclazide—Thrombocytopenia—Epirubicin—sarcoma	8.07e-05	0.000587	CcSEcCtD
Gliclazide—Hypertension—Doxorubicin—sarcoma	8.07e-05	0.000586	CcSEcCtD
Gliclazide—Tachycardia—Epirubicin—sarcoma	8.04e-05	0.000585	CcSEcCtD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—KRAS—sarcoma	8.01e-05	0.000758	CbGpPWpGaD
Gliclazide—Skin disorder—Epirubicin—sarcoma	8e-05	0.000582	CcSEcCtD
Gliclazide—VEGFA—Developmental Biology—KDR—sarcoma	8e-05	0.000757	CbGpPWpGaD
Gliclazide—Hyperhidrosis—Epirubicin—sarcoma	7.97e-05	0.000579	CcSEcCtD
Gliclazide—Arthralgia—Doxorubicin—sarcoma	7.95e-05	0.000578	CcSEcCtD
Gliclazide—Myalgia—Doxorubicin—sarcoma	7.95e-05	0.000578	CcSEcCtD
Gliclazide—Chest pain—Doxorubicin—sarcoma	7.95e-05	0.000578	CcSEcCtD
Gliclazide—Anxiety—Doxorubicin—sarcoma	7.93e-05	0.000576	CcSEcCtD
Gliclazide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—sarcoma	7.9e-05	0.000574	CcSEcCtD
Gliclazide—Discomfort—Doxorubicin—sarcoma	7.86e-05	0.000571	CcSEcCtD
Gliclazide—Dry mouth—Doxorubicin—sarcoma	7.78e-05	0.000566	CcSEcCtD
Gliclazide—Hypotension—Epirubicin—sarcoma	7.7e-05	0.00056	CcSEcCtD
Gliclazide—Confusional state—Doxorubicin—sarcoma	7.69e-05	0.000559	CcSEcCtD
Gliclazide—Infection—Doxorubicin—sarcoma	7.57e-05	0.000551	CcSEcCtD
Gliclazide—Musculoskeletal discomfort—Epirubicin—sarcoma	7.51e-05	0.000546	CcSEcCtD
Gliclazide—ALB—Hemostasis—ANGPT2—sarcoma	7.48e-05	0.000708	CbGpPWpGaD
Gliclazide—Nervous system disorder—Doxorubicin—sarcoma	7.48e-05	0.000544	CcSEcCtD
Gliclazide—Thrombocytopenia—Doxorubicin—sarcoma	7.47e-05	0.000543	CcSEcCtD
Gliclazide—Insomnia—Epirubicin—sarcoma	7.45e-05	0.000542	CcSEcCtD
Gliclazide—Tachycardia—Doxorubicin—sarcoma	7.44e-05	0.000541	CcSEcCtD
Gliclazide—Skin disorder—Doxorubicin—sarcoma	7.41e-05	0.000539	CcSEcCtD
Gliclazide—Paraesthesia—Epirubicin—sarcoma	7.4e-05	0.000538	CcSEcCtD
Gliclazide—Hyperhidrosis—Doxorubicin—sarcoma	7.37e-05	0.000536	CcSEcCtD
Gliclazide—Dyspnoea—Epirubicin—sarcoma	7.35e-05	0.000534	CcSEcCtD
Gliclazide—Somnolence—Epirubicin—sarcoma	7.33e-05	0.000533	CcSEcCtD
Gliclazide—Dyspepsia—Epirubicin—sarcoma	7.25e-05	0.000527	CcSEcCtD
Gliclazide—Hypotension—Doxorubicin—sarcoma	7.12e-05	0.000518	CcSEcCtD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—TP53—sarcoma	7.12e-05	0.000674	CbGpPWpGaD
Gliclazide—Gastrointestinal disorder—Epirubicin—sarcoma	7.11e-05	0.000517	CcSEcCtD
Gliclazide—Fatigue—Epirubicin—sarcoma	7.1e-05	0.000517	CcSEcCtD
Gliclazide—Pain—Epirubicin—sarcoma	7.05e-05	0.000512	CcSEcCtD
Gliclazide—Constipation—Epirubicin—sarcoma	7.05e-05	0.000512	CcSEcCtD
Gliclazide—VEGFA—Developmental Biology—CREB1—sarcoma	7.02e-05	0.000664	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—ENO2—sarcoma	6.99e-05	0.000662	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—HBA1—sarcoma	6.95e-05	0.000658	CbGpPWpGaD
Gliclazide—Musculoskeletal discomfort—Doxorubicin—sarcoma	6.95e-05	0.000505	CcSEcCtD
Gliclazide—Insomnia—Doxorubicin—sarcoma	6.9e-05	0.000501	CcSEcCtD
Gliclazide—Paraesthesia—Doxorubicin—sarcoma	6.85e-05	0.000498	CcSEcCtD
Gliclazide—VEGFA—Focal Adhesion—HRAS—sarcoma	6.84e-05	0.000647	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—TLE1—sarcoma	6.84e-05	0.000647	CbGpPWpGaD
Gliclazide—Dyspnoea—Doxorubicin—sarcoma	6.8e-05	0.000494	CcSEcCtD
Gliclazide—Feeling abnormal—Epirubicin—sarcoma	6.79e-05	0.000494	CcSEcCtD
Gliclazide—KCNJ11—Metabolism—ENO2—sarcoma	6.78e-05	0.000642	CbGpPWpGaD
Gliclazide—Somnolence—Doxorubicin—sarcoma	6.78e-05	0.000493	CcSEcCtD
Gliclazide—KCNJ11—Metabolism—HBA1—sarcoma	6.74e-05	0.000638	CbGpPWpGaD
Gliclazide—Gastrointestinal pain—Epirubicin—sarcoma	6.74e-05	0.00049	CcSEcCtD
Gliclazide—Dyspepsia—Doxorubicin—sarcoma	6.71e-05	0.000488	CcSEcCtD
Gliclazide—ALB—Platelet degranulation—VEGFA—sarcoma	6.67e-05	0.000632	CbGpPWpGaD
Gliclazide—Gastrointestinal disorder—Doxorubicin—sarcoma	6.58e-05	0.000479	CcSEcCtD
Gliclazide—Fatigue—Doxorubicin—sarcoma	6.57e-05	0.000478	CcSEcCtD
Gliclazide—Urticaria—Epirubicin—sarcoma	6.55e-05	0.000476	CcSEcCtD
Gliclazide—VEGFA—Developmental Biology—MMP2—sarcoma	6.53e-05	0.000618	CbGpPWpGaD
Gliclazide—Pain—Doxorubicin—sarcoma	6.52e-05	0.000474	CcSEcCtD
Gliclazide—Constipation—Doxorubicin—sarcoma	6.52e-05	0.000474	CcSEcCtD
Gliclazide—Body temperature increased—Epirubicin—sarcoma	6.51e-05	0.000474	CcSEcCtD
Gliclazide—Abdominal pain—Epirubicin—sarcoma	6.51e-05	0.000474	CcSEcCtD
Gliclazide—ALB—Response to elevated platelet cytosolic Ca2+—VEGFA—sarcoma	6.36e-05	0.000602	CbGpPWpGaD
Gliclazide—VEGFA—Axon guidance—SRC—sarcoma	6.34e-05	0.0006	CbGpPWpGaD
Gliclazide—Feeling abnormal—Doxorubicin—sarcoma	6.28e-05	0.000457	CcSEcCtD
Gliclazide—Gastrointestinal pain—Doxorubicin—sarcoma	6.23e-05	0.000453	CcSEcCtD
Gliclazide—VEGFA—Axon guidance—NRAS—sarcoma	6.1e-05	0.000577	CbGpPWpGaD
Gliclazide—Hypersensitivity—Epirubicin—sarcoma	6.07e-05	0.000441	CcSEcCtD
Gliclazide—Urticaria—Doxorubicin—sarcoma	6.06e-05	0.00044	CcSEcCtD
Gliclazide—Body temperature increased—Doxorubicin—sarcoma	6.03e-05	0.000438	CcSEcCtD
Gliclazide—Abdominal pain—Doxorubicin—sarcoma	6.03e-05	0.000438	CcSEcCtD
Gliclazide—ALB—Hemostasis—VEGFC—sarcoma	6.01e-05	0.000568	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—PLCG1—sarcoma	5.93e-05	0.000562	CbGpPWpGaD
Gliclazide—Asthenia—Epirubicin—sarcoma	5.91e-05	0.00043	CcSEcCtD
Gliclazide—ALB—Folate Metabolism—TP53—sarcoma	5.88e-05	0.000557	CbGpPWpGaD
Gliclazide—Pruritus—Epirubicin—sarcoma	5.83e-05	0.000424	CcSEcCtD
Gliclazide—VEGFA—Signaling Pathways—VEGFC—sarcoma	5.77e-05	0.000546	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—PLCG1—sarcoma	5.75e-05	0.000545	CbGpPWpGaD
Gliclazide—Diarrhoea—Epirubicin—sarcoma	5.64e-05	0.00041	CcSEcCtD
Gliclazide—Hypersensitivity—Doxorubicin—sarcoma	5.62e-05	0.000408	CcSEcCtD
Gliclazide—VEGFA—Axon guidance—EGFR—sarcoma	5.56e-05	0.000526	CbGpPWpGaD
Gliclazide—ABCC8—Neuronal System—HRAS—sarcoma	5.51e-05	0.000521	CbGpPWpGaD
Gliclazide—VEGFA—Cellular responses to stress—TP53—sarcoma	5.5e-05	0.00052	CbGpPWpGaD
Gliclazide—Asthenia—Doxorubicin—sarcoma	5.47e-05	0.000398	CcSEcCtD
Gliclazide—Dizziness—Epirubicin—sarcoma	5.45e-05	0.000396	CcSEcCtD
Gliclazide—Pruritus—Doxorubicin—sarcoma	5.39e-05	0.000392	CcSEcCtD
Gliclazide—KCNJ11—Neuronal System—HRAS—sarcoma	5.34e-05	0.000505	CbGpPWpGaD
Gliclazide—VEGFA—Axon guidance—KRAS—sarcoma	5.25e-05	0.000497	CbGpPWpGaD
Gliclazide—Vomiting—Epirubicin—sarcoma	5.24e-05	0.000381	CcSEcCtD
Gliclazide—Diarrhoea—Doxorubicin—sarcoma	5.22e-05	0.000379	CcSEcCtD
Gliclazide—Rash—Epirubicin—sarcoma	5.2e-05	0.000378	CcSEcCtD
Gliclazide—Dermatitis—Epirubicin—sarcoma	5.19e-05	0.000377	CcSEcCtD
Gliclazide—Headache—Epirubicin—sarcoma	5.16e-05	0.000375	CcSEcCtD
Gliclazide—VEGFA—Hemostasis—IL2—sarcoma	5.09e-05	0.000481	CbGpPWpGaD
Gliclazide—Dizziness—Doxorubicin—sarcoma	5.04e-05	0.000367	CcSEcCtD
Gliclazide—VEGFA—Developmental Biology—CTNNB1—sarcoma	5.01e-05	0.000474	CbGpPWpGaD
Gliclazide—Nausea—Epirubicin—sarcoma	4.89e-05	0.000356	CcSEcCtD
Gliclazide—Vomiting—Doxorubicin—sarcoma	4.85e-05	0.000352	CcSEcCtD
Gliclazide—Rash—Doxorubicin—sarcoma	4.81e-05	0.00035	CcSEcCtD
Gliclazide—Dermatitis—Doxorubicin—sarcoma	4.8e-05	0.000349	CcSEcCtD
Gliclazide—Headache—Doxorubicin—sarcoma	4.78e-05	0.000347	CcSEcCtD
Gliclazide—ALB—Hemostasis—PLCG1—sarcoma	4.72e-05	0.000447	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—FLT1—sarcoma	4.61e-05	0.000436	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—PLCG1—sarcoma	4.53e-05	0.000429	CbGpPWpGaD
Gliclazide—Nausea—Doxorubicin—sarcoma	4.53e-05	0.000329	CcSEcCtD
Gliclazide—VEGFA—Developmental Biology—SRC—sarcoma	4.53e-05	0.000428	CbGpPWpGaD
Gliclazide—VEGFA—Axon guidance—HRAS—sarcoma	4.46e-05	0.000422	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—SRC—sarcoma	4.44e-05	0.00042	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CXCR4—sarcoma	4.36e-05	0.000412	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—NRAS—sarcoma	4.35e-05	0.000412	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—ATF1—sarcoma	4.31e-05	0.000408	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—NRAS—sarcoma	4.27e-05	0.000404	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—EGFR—sarcoma	3.97e-05	0.000375	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—KRAS—sarcoma	3.75e-05	0.000355	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—KRAS—sarcoma	3.68e-05	0.000348	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—IL2—sarcoma	3.48e-05	0.00033	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—IGF1R—sarcoma	3.38e-05	0.00032	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—TP53—sarcoma	3.27e-05	0.000309	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—FOXO1—sarcoma	3.22e-05	0.000304	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—PDGFRB—sarcoma	3.21e-05	0.000304	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—HRAS—sarcoma	3.19e-05	0.000301	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—PDGFRA—sarcoma	3.16e-05	0.000299	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—HRAS—sarcoma	3.12e-05	0.000296	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—SRC—sarcoma	3.04e-05	0.000288	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—VEGFA—sarcoma	2.96e-05	0.00028	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—KDR—sarcoma	2.66e-05	0.000252	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—KIT—sarcoma	2.45e-05	0.000232	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CREB1—sarcoma	2.33e-05	0.000221	CbGpPWpGaD
Gliclazide—ALB—Metabolism—ENO2—sarcoma	2.26e-05	0.000213	CbGpPWpGaD
Gliclazide—ALB—Metabolism—HBA1—sarcoma	2.24e-05	0.000212	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—ENO2—sarcoma	2.02e-05	0.000192	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—HBA1—sarcoma	2.01e-05	0.00019	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—MDM2—sarcoma	1.93e-05	0.000183	CbGpPWpGaD
Gliclazide—ALB—Metabolism—PLCG1—sarcoma	1.91e-05	0.000181	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—ENO2—sarcoma	1.85e-05	0.000175	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—HBA1—sarcoma	1.83e-05	0.000174	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—IL2—sarcoma	1.8e-05	0.00017	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—IL2—sarcoma	1.72e-05	0.000163	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—PLCG1—sarcoma	1.72e-05	0.000163	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CCND1—sarcoma	1.68e-05	0.000159	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—JUN—sarcoma	1.68e-05	0.000159	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CTNNB1—sarcoma	1.67e-05	0.000158	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—SRC—sarcoma	1.57e-05	0.000148	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—PLCG1—sarcoma	1.57e-05	0.000148	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—VEGFA—sarcoma	1.53e-05	0.000144	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—NRAS—sarcoma	1.51e-05	0.000143	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—SRC—sarcoma	1.51e-05	0.000142	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—NRAS—sarcoma	1.45e-05	0.000137	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—MYC—sarcoma	1.35e-05	0.000128	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—EGFR—sarcoma	1.32e-05	0.000125	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—KRAS—sarcoma	1.3e-05	0.000123	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—KRAS—sarcoma	1.25e-05	0.000118	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—TP53—sarcoma	1.15e-05	0.000109	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—TP53—sarcoma	1.11e-05	0.000105	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—HRAS—sarcoma	1.1e-05	0.000104	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—HRAS—sarcoma	1.06e-05	0.0001	CbGpPWpGaD
